HC Wainwright Has Positive Forecast for DNLI FY2026 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Investment analysts at HC Wainwright lifted their FY2026 EPS estimates for shares of Denali Therapeutics in a report issued on Tuesday, January 7th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of ($0.58) per share for the year, up from their previous estimate of ($0.69). HC Wainwright has a "Buy" rating and a $87.00 price target on the stock. The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Denali Therapeutics' FY2027 earnings at $1.82 EPS.

Several other research analysts have also recently commented on the stock. Baird R W upgraded shares of Denali Therapeutics to a "strong-buy" rating in a report on Tuesday. Robert W. Baird started coverage on shares of Denali Therapeutics in a research note on Tuesday. They set an "outperform" rating and a $31.00 price objective for the company. Cantor Fitzgerald downgraded Denali Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Monday, October 7th. William Blair initiated coverage on Denali Therapeutics in a research report on Friday, January 3rd. They set an "outperform" rating for the company. Finally, Raymond James reaffirmed a "market perform" rating on shares of Denali Therapeutics in a research report on Thursday, October 10th. Two investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $38.91.

Denali Therapeutics Price Performance

Shares of DNLI traded up $0.07 during mid-day trading on Thursday, hitting $21.25. 1,245,656 shares of the company's stock were exchanged, compared to its average volume of 1,173,671. Denali Therapeutics has a 52 week low of $14.56 and a 52 week high of $33.33. The company has a market cap of $3.06 billion, a PE ratio of -7.70 and a beta of 1.39. The company has a 50-day simple moving average of $24.23 and a 200 day simple moving average of $24.86.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.03). During the same period last year, the company posted ($0.72) earnings per share.

Insider Buying and Selling

In other news, CEO Ryan J. Watts sold 40,000 shares of the firm's stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $27.69, for a total transaction of $1,107,600.00. Following the transaction, the chief executive officer now directly owns 235,807 shares of the company's stock, valued at approximately $6,529,495.83. This trade represents a 14.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Vicki L. Sato sold 1,020 shares of the business's stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $30.00, for a total value of $30,600.00. Following the completion of the sale, the director now owns 111,056 shares of the company's stock, valued at approximately $3,331,680. This trade represents a 0.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 104,518 shares of company stock valued at $2,576,982. Insiders own 7.90% of the company's stock.

Institutional Trading of Denali Therapeutics

A number of institutional investors have recently modified their holdings of DNLI. FMR LLC raised its stake in Denali Therapeutics by 3,234.3% in the third quarter. FMR LLC now owns 7,831,378 shares of the company's stock valued at $228,128,000 after purchasing an additional 7,596,508 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Denali Therapeutics by 63.2% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,749,486 shares of the company's stock valued at $109,223,000 after buying an additional 1,451,770 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Denali Therapeutics during the 2nd quarter worth approximately $24,454,000. Wellington Management Group LLP boosted its position in shares of Denali Therapeutics by 9.2% during the 3rd quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company's stock worth $312,491,000 after acquiring an additional 903,683 shares in the last quarter. Finally, Integral Health Asset Management LLC bought a new position in Denali Therapeutics in the second quarter valued at approximately $7,546,000. 92.92% of the stock is currently owned by institutional investors.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.